Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

569 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Tumour vascular targeting.
Neri D, Bicknell R. Neri D, et al. Nat Rev Cancer. 2005 Jun;5(6):436-46. doi: 10.1038/nrc1627. Nat Rev Cancer. 2005. PMID: 15928674 Review.
Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis.
Viti F, Tarli L, Giovannoni L, Zardi L, Neri D. Viti F, et al. Among authors: neri d. Cancer Res. 1999 Jan 15;59(2):347-52. Cancer Res. 1999. PMID: 9927045
A high-affinity human antibody that targets tumoral blood vessels.
Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, Dinkelborg L, Neri D, Zardi L. Tarli L, et al. Among authors: neri d. Blood. 1999 Jul 1;94(1):192-8. Blood. 1999. PMID: 10381513
Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment.
Birchler M, Viti F, Zardi L, Spiess B, Neri D. Birchler M, et al. Among authors: neri d. Nat Biotechnol. 1999 Oct;17(10):984-8. doi: 10.1038/13679. Nat Biotechnol. 1999. PMID: 10504699
Infrared photodetection for the in vivo localisation of phage-derived antibodies directed against angiogenic markers.
Birchler M, Neri G, Tarli L, Halin C, Viti F, Neri D. Birchler M, et al. Among authors: neri g, neri d. J Immunol Methods. 1999 Dec 10;231(1-2):239-48. doi: 10.1016/s0022-1759(99)00160-x. J Immunol Methods. 1999. PMID: 10648941
The use of phage display for the development of tumour targeting agents.
Nilsson F, Tarli L, Viti F, Neri D. Nilsson F, et al. Among authors: neri d. Adv Drug Deliv Rev. 2000 Sep 30;43(2-3):165-96. doi: 10.1016/s0169-409x(00)00068-5. Adv Drug Deliv Rev. 2000. PMID: 10967225 Review.
Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor.
Vitaliti A, Wittmer M, Steiner R, Wyder L, Neri D, Klemenz R. Vitaliti A, et al. Among authors: neri d. Cancer Res. 2000 Aug 15;60(16):4311-4. Cancer Res. 2000. PMID: 10969766
Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice.
Nilsson F, Kosmehl H, Zardi L, Neri D. Nilsson F, et al. Among authors: neri d. Cancer Res. 2001 Jan 15;61(2):711-6. Cancer Res. 2001. PMID: 11212273
Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin.
Demartis S, Tarli L, Borsi L, Zardi L, Neri D. Demartis S, et al. Among authors: neri d. Eur J Nucl Med. 2001 Apr;28(4):534-9. doi: 10.1007/s002590100480. Eur J Nucl Med. 2001. PMID: 11357506
Antibody-Based targeting of angiogenesis.
Halin C, Neri D. Halin C, et al. Among authors: neri d. Crit Rev Ther Drug Carrier Syst. 2001;18(3):299-339. Crit Rev Ther Drug Carrier Syst. 2001. PMID: 11442202 Review.
569 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback